1. Home
  2. CORT vs MDGL Comparison

CORT vs MDGL Comparison

Compare CORT & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated

N/A

Current Price

$81.34

Market Cap

9.7B

Sector

Health Care

ML Signal

N/A

Logo Madrigal Pharmaceuticals Inc.

MDGL

Madrigal Pharmaceuticals Inc.

N/A

Current Price

$431.93

Market Cap

11.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CORT
MDGL
Founded
1998
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.7B
11.5B
IPO Year
2001
2005

Fundamental Metrics

Financial Performance
Metric
CORT
MDGL
Price
$81.34
$431.93
Analyst Decision
Buy
Strong Buy
Analyst Count
5
19
Target Price
$141.00
★ $685.22
AVG Volume (30 Days)
★ 830.8K
275.5K
Earning Date
11-03-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.09
N/A
Revenue
★ $761,407,000.00
$180,133,000.00
Revenue This Year
$50.53
$59.43
Revenue Next Year
$46.23
$38.83
P/E Ratio
$954.56
★ N/A
Revenue Growth
★ 12.79
N/A
52 Week Low
$28.66
$399.00
52 Week High
$126.38
$615.00

Technical Indicators

Market Signals
Indicator
CORT
MDGL
Relative Strength Index (RSI) 22.77 29.12
Support Level $77.38 $416.21
Resistance Level $122.93 $546.29
Average True Range (ATR) 5.84 15.84
MACD -3.55 -1.06
Stochastic Oscillator 0.71 7.24

Price Performance

Historical Comparison
CORT
MDGL

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

Share on Social Networks: